KRKathleen A. Ryan

Kathleen A. Ryan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen A. Ryan has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Temporal trends and disparities in initiation of medications for opioid use disorder among Medicaid enrollees by race and Medicaid expansion status

    by Yujia Li, Danya M. Qato, John G. Rizk, Uzma Pathan, Jannat Saini, Bethany A DiPaula, Abree Johnson, Yu-Hua Fu, Kathleen Ryan

  • Association of Alzheimer’s Disease and Related Dementias (ADRD) With Days at Home Among Medicare Beneficiaries After a Heart Failure Hospitalization

    by Hannah W. Mitlak, Cisco G. Espinosa, Michael P. Thompson, Kathleen A. Ryan, Deborah A. Levine, Na Sun, Raya E. Kheirbek, Madeline R. Sterling, Jason Falvey

    BACKGROUND: Older adults with concomitant heart failure (HF) and Alzheimer's Disease and Related Dementias (ADRD) are at high risk for adverse outcomes, including health care utilization and mortality. Increasingly, adults with these conditions want to maximize quality of life and days at home (DAH). This study aimed to determine the association between ADRD and DAH following HF hospitalization. METHODS: This retrospective cohort analysis draws from a 20% random sample from 2017 to 2019 Medicare claims of beneficiaries who survived HF hospitalization. The primary outcome was mean DAH 6 months post-hospitalization. Exposure was defined as the presence of diagnosed ADRD, extracted from the Master Beneficiary Summary Base File Chronic Conditions subfile. Multivariable negative binomial regression was used to examine the adjusted association between ADRD and DAH, with covariates selected in accordance with the Andersen model of health care utilization. RESULTS: The 74,908 Medicare beneficiaries in the cohort had a mean age of 79.1 years (SD 11); half were men (50.0%) and 82.3% were non-Hispanic White. Overall, 18% (n=14,396) had ADRD. Beneficiaries with concomitant ADRD were older, more likely to be female, and more likely to have dual Medicaid/Medicare eligibility compared with those without ADRD. Although DAH in the 6 months preceding admission was similar, following hospitalization those with concomitant ADRD had less time at home (mean DAH 120.7 [65.9] for those with ADRD versus 136.4 [59.7] for those without ADRD). When adjusting for patient characteristics, hospitalization course, and hospital and geographic-level fixed effects, this difference persisted: patients with HF and ADRD spent an estimated 6% fewer DAH post-hospitalization (incidence rate ratio, 0.94 0.93-0.95). In the 6 months post-hospitalization, 10.2% of patients with HF and ADRD spent ≤7 DAH. The odds of spending ≤7 DAH were 24% higher for patients with ADRD (odds ratio, 1.24 [95% CI, 1.16-1.33]). CONCLUSIONS: Following HF hospitalization, Medicare beneficiaries with ADRD spent significantly fewer DAH than those without ADRD. Identifying and addressing the unmet needs of this population after hospitalization is crucial.


  • Open Access

    Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics

    by Joshua P. Lewis, Kathleen A. Ryan, Elizabeth A. Streeten, Hilary B. Whitlatch, Melanie Daue, Keith Tanner, James A. Perry, Jeffrey R. O'Connell, Alan R. Shuldiner, Braxton D. Mitchell

    Antiplatelet therapy with a P2Y12 receptor inhibitor, in combination with aspirin, is standard of care for medical management of patients with coronary artery disease, and flexibility in prescribing options among these medications offers great potential for individualizing patient care. Previously, we showed that a loss‐of‐function missense mutation (G143E) in carboxylesterase 1 (CES1), the primary enzyme responsible for clopidogrel degradation, significantly impacts on‐clopidogrel platelet aggregation and recurrent cardiovascular event risk. In the current investigation, we conducted a prospective randomized crossover study of clopidogrel (75 mg/day for 7 days) and ticagrelor (180 mg/day for 7 days) in 50 individuals stratified by CES1 G143E genotype (N = 34 143GG and 16 143GE) to determine the effect of drug choice on inhibition of platelet aggregation (IPA). Consistent with prior reports, we observed strong association between G143E and adenosine diphosphate‐stimulated platelet aggregation following clopidogrel administration (IPA = 71.6 vs. 48.0% in 143E‐allele carriers vs. non‐carriers, respectively, p = 3.8 × 10−5). Similar significant effects on platelet aggregation were also noted between 143E‐allele carriers versus non‐carriers in response to stimulation with arachidonic acid (45.8 vs. 25.8%, p = 0.04), epinephrine (44.4 vs. 18.8%, p = 0.03), and collagen (5 μg/mL, 25.8 vs. 11.4%, p = 3.7 × 10−3). In contrast, no relationship between CES1 G143E and IPA was observed following ticagrelor administration regardless of the platelet agonist used. Collectively, these data suggest that on‐clopidogrel platelet aggregation is substantially modified by CES1 G143E genotype, that this variant does not modify ticagrelor pharmacodynamics, and that more consistent inhibition of platelet aggregation may be achieved by using ticagrelor in patients who carry clopidogrel response‐modifying alleles in CES1.


  • Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles

    by Jennifer E. Huffman, Jayna Nicholas, Julie Hahn, Adam S. Heath, Laura M. Raffield, Lisa R. Yanek, Jennifer A. Brody, Florian Thibord, Laura Almasy, Traci M. Bartz, et al.

    Genetic studies have identified numerous regions associated with plasma fibrinogen levels in Europeans, yet missing heritability and limited inclusion of non-Europeans necessitates further studies with improved power and sensitivity. Compared with array-based genotyping, whole-genome sequencing (WGS) data provide better coverage of the genome and better representation of non-European variants. To better understand the genetic landscape regulating plasma fibrinogen levels, we meta-analyzed WGS data from the National Heart, Lung, and Blood Institute’s Trans-Omics for Precision Medicine (TOPMed) program (n = 32 572), with array-based genotype data from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (n = 131 340) imputed to the TOPMed or Haplotype Reference Consortium panel. We identified 18 loci that have not been identified in prior genetic studies of fibrinogen. Of these, 4 are driven by common variants of small effect with reported minor allele frequency (MAF) at least 10 percentage points higher in African populations. Three signals (SERPINA1, ZFP36L2, and TLR10) contain predicted deleterious missense variants. Two loci, SOCS3 and HPN, each harbor 2 conditionally distinct, noncoding variants. The gene region encoding the fibrinogen protein chain subunits (FGG;FGB;FGA) contains 7 distinct signals, including 1 novel signal driven by rs28577061, a variant common in African ancestry populations but extremely rare in Europeans (MAFAFR = 0.180; MAFEUR = 0.008). Through phenome-wide association studies in the VA Million Veteran Program, we found associations between fibrinogen polygenic risk scores and thrombotic and inflammatory disease phenotypes, including an association with gout. Our findings demonstrate the utility of WGS to augment genetic discovery in diverse populations and offer new insights for putative mechanisms of fibrinogen regulation.


  • A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

    by Paul S. de Vries, Paula Reventun, Michael R. Brown, Adam S. Heath, Jennifer E. Huffman, Ngoc-Quynh Le, Allison Bebo, Jennifer A. Brody, Gerard Temprano-Sagrera, Laura M. Raffield, et al.

    Coagulation factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) are critical to coagulation and platelet aggregation. We leveraged whole-genome sequence data from the Trans-Omics for Precision Medicine (TOPMed) program along with TOPMed-based imputation of genotypes in additional samples to identify genetic associations with circulating FVIII and VWF levels in a single-variant meta-analysis, including up to 45 289 participants. Gene-based aggregate tests were implemented in TOPMed. We identified 3 candidate causal genes and tested their functional effect on FVIII release from human liver endothelial cells (HLECs) and VWF release from human umbilical vein endothelial cells. Mendelian randomization was also performed to provide evidence for causal associations of FVIII and VWF with thrombotic outcomes. We identified associations (P < 5 × 10−9) at 7 new loci for FVIII (ST3GAL4, CLEC4M, B3GNT2, ASGR1, F12, KNG1, and TREM1/NCR2) and 1 for VWF (B3GNT2). VWF, ABO, and STAB2 were associated with FVIII and VWF in gene-based analyses. Multiphenotype analysis of FVIII and VWF identified another 3 new loci, including PDIA3. Silencing of B3GNT2 and the previously reported CD36 gene decreased release of FVIII by HLECs, whereas silencing of B3GNT2, CD36, and PDIA3 decreased release of VWF by HVECs. Mendelian randomization supports causal association of higher FVIII and VWF with increased risk of thrombotic outcomes. Seven new loci were identified for FVIII and 1 for VWF, with evidence supporting causal associations of FVIII and VWF with thrombotic outcomes. B3GNT2, CD36, and PDIA3 modulate the release of FVIII and/or VWF in vitro.


  • Top Cited Papers
    Open Access

    Multi-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implications

    by Rosalie B. T. M. Sterenborg, Inga Steinbrenner, Yong Li, Melissa N. Bujnis, Tatsuhiko Naito, Eirini Marouli, Tessel E. Galesloot, Oladapo Babajide, Laura Andreasen, Arne Astrup, et al.

    To date only a fraction of the genetic footprint of thyroid function has been clarified. We report a genome-wide association study meta-analysis of thyroid function in up to 271,040 individuals of European ancestry, including reference range thyrotropin (TSH), free thyroxine (FT4), free and total triiodothyronine (T3), proxies for metabolism (T3/FT4 ratio) as well as dichotomized high and low TSH levels. We revealed 259 independent significant associations for TSH (61% novel), 85 for FT4 (67% novel), and 62 novel signals for the T3 related traits. The loci explained 14.1%, 6.0%, 9.5% and 1.1% of the total variation in TSH, FT4, total T3 and free T3 concentrations, respectively. Genetic correlations indicate that TSH associated loci reflect the thyroid function determined by free T3, whereas the FT4 associations represent the thyroid hormone metabolism. Polygenic risk score and Mendelian randomization analyses showed the effects of genetically determined variation in thyroid function on various clinical outcomes, including cardiovascular risk factors and diseases, autoimmune diseases, and cancer. In conclusion, our results improve the understanding of thyroid hormone physiology and highlight the pleiotropic effects of thyroid function on various diseases.


  • Open Access

    Polygenic Risk Score Associates With Atherosclerotic Plaque Characteristics at Autopsy

    by Anne Cornelissen, Neel V. Gadhoke, Kathleen Ryan, Chani J. Hodonsky, Rebecca Mitchell, Nathan A. Bihlmeyer, ThuyVy Duong, Zhifen Chen, Armelle Dikongue, Atsushi Sakamoto, et al.

    BACKGROUND: Polygenic risk scores (PRSs) for coronary artery disease (CAD) potentially improve cardiovascular risk prediction. However, their relationship with histopathologic features of CAD has never been examined systematically. METHODS: From 4327 subjects referred to CVPath by the State of Maryland Office Chief Medical Examiner for sudden death between 1994 and 2015, 2455 cases were randomly selected for genotyping. We generated PRS from 291 known CAD risk loci. Detailed histopathologic examination of the coronary arteries was performed in all subjects. The primary study outcome measurements were histopathologic plaque features determining severity of atherosclerosis, including %stenosis, calcification, thin-cap fibroatheromas, and thrombotic CAD. RESULTS: After exclusion of cases with insufficient DNA sample quality or with missing data, 954 cases (mean age, 48.8±14.7 years; 75.7% men) remained in the final study cohort. Subjects in the highest PRS quintile exhibited more severe atherosclerosis compared with subjects in the lowest quintile, with greater %stenosis (80.3%±27.0% versus 50.4%±38.7%; adjusted P P =0.004) and thin-cap fibroatheroma (26.7% versus 9.5%; adjusted P =0.007). Even after adjustment for traditional CAD risk factors, subjects within the highest PRS quintile had higher odds of severe atherosclerosis (ie, ≥75% stenosis; adjusted odds ratio, 3.77 [95% CI, 2.10–6.78]; P P P <0.001). No statistically significant associations were observed with plaque erosion after adjusting for covariates. CONCLUSIONS: This is the first autopsy study investigating associations between PRS and atherosclerosis severity at the histopathologic level in subjects with sudden death. Our pathological analysis suggests PRS correlates with plaque burden and features of advanced atherosclerosis and may be useful as a method for CAD risk stratification, especially in younger subjects.


  • Whole-genome sequencing uncovers two loci for coronary artery calcification and identifies ARSE as a regulator of vascular calcification

    by Paul S. de Vries, Matthew P. Conomos, Kuldeep Singh, Christopher J. Nicholson, Deepti Jain, Natalie R. Hasbani, Wanlin Jiang, Sujin Lee, Christian L. Lino Cardenas, Sharon M. Lutz, et al.

    Coronary artery calcification (CAC) is a measure of atherosclerosis and a well-established predictor of coronary artery disease (CAD) events. Here we describe a genome-wide association study of CAC in 22,400 participants from multiple ancestral groups. We confirmed associations with four known loci and identified two additional loci associated with CAC (ARSE and MMP16), with evidence of significant associations in replication analyses for both novel loci. Functional assays of ARSE and MMP16 in human vascular smooth muscle cells (VSMCs) demonstrate that ARSE is a promoter of VSMC calcification and VSMC phenotype switching from a contractile to a calcifying or osteogenic phenotype. Furthermore, we show that the association of variants near ARSE with reduced CAC is likely explained by reduced ARSE expression with the G allele of enhancer variant rs5982944. Our study highlights ARSE as an important contributor to atherosclerotic vascular calcification and a potential drug target for vascular calcific disease.


  • Open Access

    Missense variants in SORT1 are associated with LDL-C in an Amish population

    by Kelly A. Mitok, Kathryn L. Schueler, Sarah M. King, Joseph Orr, Kathleen A. Ryan, Mark P. Keller, Ronald M. Krauss, Braxton D. Mitchell, Alan R. Shuldiner, Alan D. Attie


  • Top Cited Papers

    Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease

    by Yanhua Chen, Xiaomeng Du, Annapurna Kuppa, Mary F. Feitosa, Lawrence F. Bielak, Jeffrey R. O’COnnell, Solomon K. Musani, Xiuqing Guo, Bratati Kahali, Vincent L. Chen, et al.

    Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no effective treatments. We carried out a genome-wide association study (GWAS) meta-analysis of imaging (n = 66,814) and diagnostic code (3,584 cases versus 621,081 controls) measured NAFLD across diverse ancestries. We identified NAFLD-associated variants at torsin family 1 member B (TOR1B), fat mass and obesity associated (FTO), cordon-bleu WH2 repeat protein like 1 (COBLL1)/growth factor receptor-bound protein 14 (GRB14), insulin receptor (INSR), sterol regulatory element-binding transcription factor 1 (SREBF1) and patatin-like phospholipase domain-containing protein 2 (PNPLA2), as well as validated NAFLD-associated variants at patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily 2 (TM6SF2), apolipoprotein E (APOE), glucokinase regulator (GCKR), tribbles homolog 1 (TRIB1), glycerol-3-phosphate acyltransferase (GPAM), mitochondrial amidoxime-reducing component 1 (MARC1), microsomal triglyceride transfer protein large subunit (MTTP), alcohol dehydrogenase 1B (ADH1B), transmembrane channel like 4 (TMC4)/membrane-bound O-acyltransferase domain containing 7 (MBOAT7) and receptor-type tyrosine-protein phosphatase δ (PTPRD). Implicated genes highlight mitochondrial, cholesterol and de novo lipogenesis as causally contributing to NAFLD predisposition. Phenome-wide association study (PheWAS) analyses suggest at least seven subtypes of NAFLD. Individuals in the top 10% and 1% of genetic risk have a 2.5-fold to 6-fold increased risk of NAFLD, cirrhosis and hepatocellular carcinoma. These genetic variants identify subtypes of NAFLD, improve estimates of disease risk and can guide the development of targeted therapeutics.